

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/748,233
Date Submitted: January 27, 2009 <i>(use as many sheets as necessary)</i>				Filing Date	12/31/2003
				First Named Inventor	Robert MARTUZA
				Group Art Unit	1632
				Examiner Name	Wu-Cheng Winston Shen
Sheet	1	of	2	Attorney Docket Number	066683-0196

JAN 27 2009

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
E1	5,585,096			Martuza et al	12/1996	
E2	5,571,515			Scott et al.	11/1996	
E3	6,699,468			Martuza et al.	03/2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
E4		WO 96/00007			GEORGETOWN UNIVERSITY	01/1996		
E5		WO 96/38741			BRITISH TECHNOLOGY GROUP LIMITED	12/1986		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
E6		HUBENTHAL-VOSS et al., MAPPING OF FUNCTIONAL AND ANTIGENIC DOMAINS OF THE ALPHA 4 PROTEIN OF HERPES SIMPLEX VIRUS 1. J VIROL. 62(2): 454-62, 1988.	
E7		Oppenheim et al., "Prospects for Cytokine and Chemokine Biotherapy", Clinical Cancer Research, Vol. 3, pp. 2682-2686, 1997	
E8		Parmiani et al., "Cytokine Gene Transduction in the Immunotherapy of Cancer", Adv. Pharmacol., Vo. 40, pp. 259-307, 1997	
E9		Rollins, Barrett J., "Chemokines", Blood, Vol. 90, No. 3 pp. 909-928, 1997	
E10		Andreansky et al., "Treatment of Intracranial Gliomas in Immunocompetent Mice Using Herpes Simplex Viruses that Express Murine Interleukins", Gene Therapy, Vol. 5, pp. 121-130, 1998	
E11		Hu et al., "A Phase I Study of OncoVEX ^{GM-CSF} , a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor", Clinical Cancer Research, Vo. 12 (22), pp. 6737-6747, 2006	

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	03/07/2009
--------------------	-------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/748,233
Date Submitted: January 27, 2009 <i>(use as many sheets as necessary)</i>			Filing Date	12/31/2003
			First Named Inventor	Robert MARTUZA
			Group Art Unit	1632
			Examiner Name	Wu-Cheng Winston Shen
Sheet	2	of	2	Attorney Docket Number
NON PATENT LITERATURE DOCUMENTS				

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	E12	Iida et al., "Protective Activity of Recombinant Cytokines Against Sendai Virus and Herpes Simplex Virus (HSV) Infections in Mice", <i>Vaccine</i> , Vo. 7, pp. 229-233, 1989	
	E13	Liu et al., "ICP34.5 Deleted Herpes Simplex Virus with Enhanced Oncolytic, Immune Stimulating, and Anti-Tumour Properties", <i>Gene Therapy</i> , Vo. 10, pp. 292-303, 2003	
	E14	Matsuo et al., "Interleukin-12 Protects Thermally Injured Mice from Herpes Simplex Virus Type 1 Infection", <i>Journal of Leukocyte Biology</i> , Vo. 59, pp. 623-630, 1996	
	E15	Parker et al., "Engineered Herpes Simplex Virus Expressing IL-12 in the Treatment of Experimental Murine Brain Tumors", <i>PNAS</i> , Vo. 97 (5), pp. 2208-2213, 2000	
	E16	Vaghese et al., "Systemic Oncolytic Herpes Virus Therapy of Poorly Immunogenic Prostate Cancer Metastatic to Lung", <i>Clinical Cancer Research</i> , Vo. 12 (9), pp. 2919-2927, 2006	
	E17	Vaghese et al., "Enhanced Therapeutic Efficacy of IL-12, but not GM-CSF, Expressing Oncolytic Herpes Simplex Virus for Transgenic Mouse Derived Prostate Cancers", <i>Cancer Gene Therapy</i> , Vo. 13, pp. 253-265, 2006	
	E18	Wong et al., "Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12", <i>Clinical Cancer Research</i> , Vo. 10, pp. 251-259, 2004	
	E19	Wong et al., "Angiogenesis Inhibition by an Oncolytic Herpes Virus Expressing Interleukin 12", <i>Clinical Cancer Research</i> , Vo. 10, pp. 4509-4516, 2004	
	E20	Wong et al., "Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell Carcinoma", <i>Human Gene Therapy</i> , Vo. 12, pp. 253-265, 2001	
	E21	Meignier et al., "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020: Construction and Evaluation in Rodents", <i>The Journal of Infectious Diseases</i> , Vo. 158 (3), pp. 602-614, 1988	
	E22	MEKO et al., (1995) <i>Cancer Research</i> , Vol. 55(1), 4765-4770.	
	E23	RAMSHAW et al., (1997) <i>Immunological Reviews</i> , Vol. 159, pp. 119-135.	
	E24	BRAMSON et al., (1996) <i>Human Gene Therapy</i> , Vol. 7, No. 16, 1995-2002.	

Examiner Signature	/Wu-Cheng Winston Shen/	Date Considered	03/07/2009
--------------------	-------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.